Advanced search
Publication Cover
mAbs Volume 7, 2015 - Issue 2
Submit an article Journal homepage
1,504
Views
19
CrossRef citations to date
0
Altmetric
Reports

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

Valerie R WiersmaUniversity of Groningen; University Medical Center Groningen (UMCG); Department of Surgery; Translational Surgical Oncology; Groningen, The Netherlands
,
Marco de BruynUniversity of Groningen; University Medical Center Groningen (UMCG); Department of Obstetrics and Gynecology; Groningen, The Netherlands
,
Ce ShiHealth Ministry Key Lab of Cell Transplantation; Heilongjiang Institute of Hematology and Oncology; Department of Hematology; The First Affiliated Hospital; Harbin Medical University; Harbin, China
,
Marloes JM GoodenUniversity of Groningen; University Medical Center Groningen (UMCG); Department of Surgery; Translational Surgical Oncology; Groningen, The Netherlands;University of Groningen; University Medical Center Groningen (UMCG); Department of Obstetrics and Gynecology; Groningen, The Netherlands
,
Maartje CA WoutersUniversity of Groningen; University Medical Center Groningen (UMCG); Department of Obstetrics and Gynecology; Groningen, The Netherlands
,
Douwe F SamploniusUniversity of Groningen; University Medical Center Groningen (UMCG); Department of Surgery; Translational Surgical Oncology; Groningen, The Netherlands
,
Djoke HendriksUniversity of Groningen; University Medical Center Groningen (UMCG); Department of Surgery; Translational Surgical Oncology; Groningen, The Netherlands
,
Hans W NijmanUniversity of Groningen; University Medical Center Groningen (UMCG); Department of Obstetrics and Gynecology; Groningen, The Netherlands
,
Yunwei WeiHealth Ministry Key Lab of Cell Transplantation; Heilongjiang Institute of Hematology and Oncology; Department of Hematology; The First Affiliated Hospital; Harbin Medical University; Harbin, China
,
Jin ZhouHealth Ministry Key Lab of Cell Transplantation; Heilongjiang Institute of Hematology and Oncology; Department of Hematology; The First Affiliated Hospital; Harbin Medical University; Harbin, China
,
Wijnand HelfrichUniversity of Groningen; University Medical Center Groningen (UMCG); Department of Surgery; Translational Surgical Oncology; Groningen, The Netherlands;Health Ministry Key Lab of Cell Transplantation; Heilongjiang Institute of Hematology and Oncology; Department of Hematology; The First Affiliated Hospital; Harbin Medical University; Harbin, ChinaCorrespondence[email protected] [email protected]
&
Edwin BremerUniversity of Groningen; University Medical Center Groningen (UMCG); Department of Surgery; Translational Surgical Oncology; Groningen, The Netherlands;Health Ministry Key Lab of Cell Transplantation; Heilongjiang Institute of Hematology and Oncology; Department of Hematology; The First Affiliated Hospital; Harbin Medical University; Harbin, ChinaCorrespondence[email protected] [email protected]
 show all
Pages 321-330 | Received 29 Aug 2014, Accepted 15 Dec 2014, Published online: 11 Mar 2015

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Djoke Hendriks, Yuan He, Iris Koopmans, Valerie R. Wiersma, Robert J. van Ginkel, Douwe F. Samplonius, Wijnand Helfrich & Edwin Bremer. (2016) Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. OncoImmunology 5:8.
Read now

Articles from other publishers (18)

Paresh Vishwasrao, Gongbo Li, Justin C. Boucher, D. Lynne Smith & Susanta K. Hui. (2022) Emerging CAR T Cell Strategies for the Treatment of AML. Cancers 14:5, pages 1241.
Crossref
Yasaman Asaadi, Fatemeh Fazlollahi Jouneghani, Sara Janani & Fatemeh Rahbarizadeh. (2021) A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomarker Research 9:1.
Crossref
Lok Lam Ngai, Connie Y. Ma, Orla Maguire, An D. Do, Alberto Robert, Aaron C. Logan, Elizabeth A. Griffiths, Michael J. Nemeth, Cherie Green, Tony Pourmohamad, Bo J. van Kuijk, Alexander N. Snel, Zinia W. Kwidama, Bianca Venniker‐Punt, James Cooper, Markus G. Manz, Bjørn T. Gjertsen, Linda Smit, Gert J. Ossenkoppele, Jeroen J. W. M. Janssen, Jacqueline Cloos & Teiko Sumiyoshi. (2021) Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients. European Journal of Haematology 107:3, pages 343-353.
Crossref
Jinghua Wang, Weida Wang, Hao Chen, Wenmin Li, Tian Huang, Weiya Zhang, Wei Ling, Peilong Lai, Yulian Wang, Suxia Geng, Minming Li, Xin Du & Jianyu Weng. (2021) C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study. BioMed Research International 2021, pages 1-9.
Crossref
David Deng & Khalid Shah. (2020) TRAIL of Hope Meeting Resistance in Cancer. Trends in Cancer 6:12, pages 989-1001.
Crossref
Marian A. Ackun‐Farmmer, Kharimat L. Alatise, Griffin Cross & Danielle S. W. Benoit. (2020) Ligand Density Controls C‐Type Lectin‐Like Molecule‐1 Receptor–Specific Uptake of Polymer Nanoparticles. Advanced Biosystems 4:11, pages 2000172.
Crossref
Natasha Ustyanovska Avtenyuk, Nienke Visser, Edwin Bremer & Valerie R. Wiersma. (2020) The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. International Journal of Molecular Sciences 21:21, pages 7820.
Crossref
Hongbing Ma, Iyer Swaminathan Padmanabhan, Simrit Parmar & Yuping Gong. (2019) Targeting CLL-1 for acute myeloid leukemia therapy. Journal of Hematology & Oncology 12:1.
Crossref
Justin R. Klesmith, Lihe Su, Lan Wu, Ian A. Schrack, Fay J. Dufort, Alyssa Birt, Christine Ambrose, Benjamin J. Hackel, Roy R. Lobb & Paul D. Rennert. (2019) Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins. Molecular Pharmaceutics 16:8, pages 3544-3558.
Crossref
Wajant. (2019) Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation. Cancers 11:7, pages 954.
Crossref
Jinghua Wang, Siyu Chen, Wei Xiao, Wende Li, Liang Wang, Shuo Yang, Weida Wang, Liping Xu, Shuangye Liao, Wenjian Liu, Yang Wang, Nawei Liu, Jianeng Zhang, Xiaojun Xia, Tiebang Kang, Gong Chen, Xiuyu Cai, Han Yang, Xing Zhang, Yue Lu & Penghui Zhou. (2018) CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. Journal of Hematology & Oncology 11:1.
Crossref
Agathe Dubuisson & Olivier Micheau. (2017) Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy. Antibodies 6:4, pages 16.
Crossref
Yuan He, Peter E. van Bommel, Douwe F. Samplonius, Edwin Bremer & Wijnand Helfrich. (2017) A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. Scientific Reports 7:1.
Crossref
D. Hendriks, G. Choi, M. de Bruyn, V.R. Wiersma & E. Bremer. 2017. 289 383 .
Lubna Danish, Daniela Stöhr, Peter Scheurich & Nadine Pollak. 2017. TRAIL, Fas Ligand, TNF and TLR3 in Cancer. TRAIL, Fas Ligand, TNF and TLR3 in Cancer 27 57 .
D de Miguel, J Lemke, A Anel, H Walczak & L Martinez-Lostao. (2016) Onto better TRAILs for cancer treatment. Cell Death & Differentiation 23:5, pages 733-747.
Crossref
Yaghoub Safdari, Vahideh Ahmadzadeh, Masoumeh Khalili, Hossein Zarei Jaliani, Vahid Zarei & Vahid Erfani-Moghadam. (2016) Use of Single-Chain Antibody Derivatives for Targeted Drug Delivery. Molecular Medicine 22:1, pages 258-270.
Crossref
Shuzhong Li. (2015) Correlation between Polymorphism of TRAIL Gene and Condition of Intervertebral Disc Degeneration. Medical Science Monitor 21, pages 2282-2287.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.